[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484145":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":40,"responsibleParty":56,"collaborators":58,"id":61,"slug":32,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":32,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":86,"whyStopped":32,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Medical treatment","EXPERIMENTAL","Combination therapy with subcutaneous infliximab and azathioprine",[13],"Drug: Azathioprine + infliximab",{"label":15,"type":16,"description":17,"interventionNames":18},"Surgery","ACTIVE_COMPARATOR","Intestinal resection",[19],"Procedure: Intestinal resection",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Azathioprine + infliximab","Combination therapy using 2-2.5 mg\u002Fkg oral azathioprine plus subcutaneous infliximab",[9],[27],"Imurel, Remsima",{"type":29,"name":17,"description":30,"armGroupLabels":31,"otherNames":32},"PROCEDURE","Ileocolonic or small bowel resection",[15],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Catherine Le Berre","CONTACT","(0)2 40 08 31 52","+ 33","catherine.leberre@chu-nantes.fr",[41],{"facility":42,"status":32,"city":43,"state":32,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"CHU de Nantes","Nantes","44093","France",{"type":47,"coordinates":48},"Point",[49,50],-1.55336,47.21725,{"lat":50,"lon":49},[53],{"name":54,"role":36,"phone":55,"phoneExt":32,"email":39},"Catherine LE BERRE","0240083152",{"type":57,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[59],{"name":60,"class":6},"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","100484145",false,"NCT05584228","Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease","SyMptomAtic Stricturing Small Bowel CRohn's Disease - Medical Treatment Versus Surgery, a Prospective, Multi-centre, Randomized, Non-inferiority Trial","SMART","Inclusion Criteria:\n\n* Age between 18 and 70 years\n* Male or female\n* Documented small bowel CD with intestinal stricture(s) identified on CT, MRI or endoscopy, AND responsible for obstructive symptoms\n* CREOLE score \\> 2\n\nExclusion Criteria:\n\n* Adults under guardianship, safeguard justice or trusteeship\n* Pregnant or breastfeeding female\n* Acute bowel obstruction requiring urgent surgical intervention\n* Suspected or confirmed gastrointestinal perforation\n* Concurrent active perianal sepsis\n* Internal fistulizing disease in association with strictures\n* Colonic stenosis and\u002For colonic active disease at screening endoscopy\n* Contra-indication to surgery, general anesthesia, anti-TNF, thiopurines\n* Use of corticosteroids (prednisolone \\> 20 mg daily or equivalent) within 4 weeks prior to visit V0\n* Treatment with any biologics within 8 weeks before visit V0\n* Presence of a stoma\n* HIV\u002FHCV\u002FHBV infection","ALL","18 Years","70 Years",{"count":72,"type":73},150,"ESTIMATED","INTERVENTIONAL",[76],"NA","The objective of the SMART trial is to compare a combination therapy using azathioprine and subcutaneous infliximab versus ileocecal resection in patients with symptomatic small bowel Crohn's disease.",[79],"Crohn Disease",[81,82,83,84,85],"Crohn's disease","stricture","resection","infliximab","azathioprine","NOT_YET_RECRUITING","2026-06-22",{"date":89,"type":90},"2026-06-23","ACTUAL",{"date":92,"type":73},"2026-10-01",{"date":94,"type":73},"2031-04-01",{"name":5,"class":6},1]